PreludeDx

📍 Laguna Hills, United States👥 47 employees💰 Last funded Jan 2022
Biotechnology Research🌐 preludedx.com
Website LinkedIn
PreludeDx was founded to deliver actionable tools to manage early stage breast cancer. PreludeDx's first diagnostic test, DCISionRT is the result of over a decade of research and development focused on DCIS. PreludeDx began developing its DCIS test in 2009 after licensing technology from University of California, San Francisco. DCISionRT’s technology was designed from the beginning to address the critical question faced by patients with DCIS. What is my risk of recurrence and what treatment is appropriate?
1
Total investors
0
Early stage
0
Mid stage
0
Late stage
—
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in PreludeDx?
PreludeDx has 1 investors on record on gritt.io.
When did PreludeDx last raise funding?
The most recent investment in PreludeDx recorded on gritt.io was in January 2022.
What industry is PreludeDx in?
PreludeDx operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is PreludeDx based?
PreludeDx is headquartered in Laguna Hills, United States.